Atlas Trials

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Clinical trial NCT02042391 · COMPLETED

Trial details

NCT number
NCT02042391
Sponsor
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Posttransplant Lymphoproliferative Disorder
Start date
2015-02-03
Primary completion
2021-07-13
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.